These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 9594556)

  • 1. [Prolonged treatment with slow release nicotinic acid in patients with type II hyperlipidemia].
    Chojnowska-Jezierska J; Adamska-Dyniewska H
    Pol Arch Med Wewn; 1997 Nov; 98(11):391-9. PubMed ID: 9594556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
    McKenney JM; Proctor JD; Harris S; Chinchili VM
    JAMA; 1994 Mar; 271(9):672-7. PubMed ID: 8309029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover.
    Seed M; O'Connor B; Perombelon N; O'Donnell M; Reaveley D; Knight BL
    Atherosclerosis; 1993 Jun; 101(1):61-8. PubMed ID: 8216503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia.
    Davignon J; Roederer G; Montigny M; Hayden MR; Tan MH; Connelly PW; Hegele R; McPherson R; Lupien PJ; Gagné C
    Am J Cardiol; 1994 Feb; 73(5):339-45. PubMed ID: 8109547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Induracin, prolonged-action nicotinic acid, in the treatment of atherogenic dyslipoproteinemia].
    Kiseleva NG
    Klin Med (Mosk); 1994; 72(3):20-4. PubMed ID: 7990345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical management of dyslipidemia with elevated lipoprotein(a).
    Riche DM; East HE; Priest HM
    J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy.
    Tuteja S; Wang L; Dunbar RL; Chen J; DerOhannessian S; Marcovina SM; Elam M; Lader E; Rader DJ
    Pharmacogenet Genomics; 2017 Aug; 27(8):285-293. PubMed ID: 28628560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia.
    Császár A; Karádi I; Köszegi G; Pados G; Németh-Csóka M; Pichler M; Romics L
    Klin Wochenschr; 1990; 68 Suppl 22():96-8. PubMed ID: 2087089
    [No Abstract]   [Full Text] [Related]  

  • 14. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
    Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of one-year treatment with low simvastatin doses on lipids and Lp(a) in patients with significant hypercholesterolemia].
    Adamska-Dyniewska H; Chojnowska-Jezierska J
    Pol Arch Med Wewn; 1998 May; 99(5):366-72. PubMed ID: 9816885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study.
    Warnholtz A; Wild P; Ostad MA; Elsner V; Stieber F; Schinzel R; Walter U; Peetz D; Lackner K; Blankenberg S; Munzel T
    Atherosclerosis; 2009 May; 204(1):216-21. PubMed ID: 18822413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia.
    Vacek JL; Dittmeier G; Chiarelli T; White J; Bell HH
    Am J Cardiol; 1995 Jul; 76(3):182-4. PubMed ID: 7611158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid modifying action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in patients with ischaemic heart disease.
    Santanu G; Suhrita P; Mookerjee S; Tania K; Mita S; Pramit G; Sharmila G; Miraj M; Debdutta M
    Indian Heart J; 2011; 63(5):434-7. PubMed ID: 23550422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.